title: [Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?].
authors.affiliation: Klinika Chorób Serca, Akademia Medyczna im. Piastów Śląskich, Wrocław. krystian85@hotmail.com
authors.forename: Krystian
authors.initials: K
authors.lastname: Josiak
authors.forename: Ewa
authors.initials: E
authors.lastname: Inorowicz
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Kremis
authors.forename: Ewa Anita
authors.initials: EA
authors.lastname: Jankowska
authors.forename: Waldemar
authors.initials: W
authors.lastname: Banasiak
authors.forename: Piotr
authors.initials: P
authors.lastname: Ponikowski
mesh_terms: D002243:Carbolines / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D000068581:Tadalafil; D016896:Treatment Outcome; D014227:Triazines / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride
chemical_list: D002243:Carbolines; D007093:Imidazoles; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate